Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - teicoplanin - powder and solvent for solution for injection/infusion - 400 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - teicoplanin - powder and solvent for solution for injection/infusion - 200 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - teicoplanin - powder and solvent for solution for injection/infusion - 400 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - teicoplanin - powder and solvent for solution for injection/infusion - 200 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - teicoplanin - powder for solution for injection/infusion - 200 milligram(s) - glycopeptide antibacterials; teicoplanin

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - teicoplanin - powder for solution for injection/infusion - 400 milligram(s) - glycopeptide antibacterials; teicoplanin

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - teicoplanin, quantity: 400 mg - injection, powder for - excipient ingredients: sodium chloride - targocid is indicated for the treatment of the following infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including b-lactam antibiotics: - bone - osteomyelitis; joints - septic arthritis; blood - non-cardiac bacteraemia, septicaemia.